Teprotumumab for Thyroid-Associated Ophthalmopathy

Overview of attention for article published in New England Journal of Medicine, May 2017

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

news: 71 news outlets
blogs: 7 blogs
policy: 1 policy source
twitter: 110 X users
patent: 25 patents

facebook: 9 Facebook pages
wikipedia: 1 Wikipedia page
googleplus: 2 Google+ users
f1000: 1 research highlight platform
guideline: 4 clinical guideline sources

Readers on

mendeley: 416 Mendeley

So far, Altmetric has seen 7 posts from 7 blogs.

Teprotumumab-trbw

New Drug Approvals, 25 Jan 2020

Tepezza (teprotumumab-trbw) Company: Horizon Therapeutics…

FDA recommends approval of eye drug tested in Portland

Oregon Health & Sciences University, 16 Dec 2019

OHSU is part of multi-center study testing teprotumumab for thyroid eye disease.

Teprotumumab bij een actieve oogziekte van Graves

Schildkliertje, 26 Oct 2017

De behandeling van de oogziekte blijft moeizaam en lastig. De oogziekte komt voor bij de ziekte van Graves en Hashimoto.

Primecuts – This Week in the Journals

Clinical Correlations, 22 May 2017

By Michelle Lo…

This page shows the most recent blog posts that mention this research output. Click here to find out how to access more activity, including 3 additional blog posts.